Cargando…

Teclistamab impairs detection of BCMA CAR-T cells

Detalles Bibliográficos
Autores principales:	Glatte, Bettina, Wenk, Kerstin, Grahnert, Anja, Friedrich, Maik, Merz, Maximilian, Vucinic, Vladan, Fischer, Luise, Reiche, Kristin, Alb, Miriam, Hudecek, Michael, Franz, Paul, Fricke, Stephan, Platzbecker, Uwe, Koehl, Ulrike, Sack, Ulrich, Boldt, Andreas, Hauschildt, Sunna, Weiss, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393749/ https://www.ncbi.nlm.nih.gov/pubmed/37026812 http://dx.doi.org/10.1182/bloodadvances.2023009714

Ejemplares similares

Production and Application of CAR T Cells: Current and Future Role of Europe
por: Vucinic, Vladan, et al.
Publicado: (2021)

Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
por: Blache, Ulrich, et al.
Publicado: (2021)

Comparison of Three CD3-Specific Separation Methods Leading to Labeled and Label-Free T Cells
por: Weiss, Ronald, et al.
Publicado: (2021)

The Impact of Rubella Virus Infection on a Secondary Inflammatory Response in Polarized Human Macrophages
por: Schilling, Erik, et al.
Publicado: (2021)

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

NAD metabolites interfere with proliferation and functional properties of THP-1 cells
por: Petin, Katharina, et al.
Publicado: (2019)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023)

The orthologue of the "acatalytic" mammalian ART4 in chicken is an arginine-specific mono-ADP-ribosyltransferase
por: Grahnert, Andreas, et al.
Publicado: (2008)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

P1415: CELLULAR DYNAMICS IN RESPONDERS AND NON-RESPONDERS AFTER THE TREATMENT OF PATIENTS WITH AGGRESSIVE B-ZELL LYMPHOMAS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
por: Walter Georgi, Thomas, et al.
Publicado: (2023)

Teclistamab: First Approval
por: Kang, Connie
Publicado: (2022)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells
por: Reichman, Avinoam, et al.
Publicado: (2022)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
por: Banerjee, Rahul, et al.
Publicado: (2022)

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
por: Rodriguez-Marquez, Paula, et al.
Publicado: (2022)

High antigen density of BCMA: friend or foe to CAR T cells?
por: Gaballa, Mahmoud R, et al.
Publicado: (2022)

Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
por: Li, Dan, et al.
Publicado: (2022)

CD14 Is Involved in the Interferon Response of Human Macrophages to Rubella Virus Infection
por: Schilling, Erik, et al.
Publicado: (2022)

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma
por: Sjöstrand, Maria, et al.
Publicado: (2023)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

CAR T cells for treating autoimmune diseases
por: Blache, Ulrich, et al.
Publicado: (2023)

Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR
por: Zhang, Wenli, et al.
Publicado: (2021)

Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages
por: Joedicke, Jara J., et al.
Publicado: (2021)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: van de Donk, N., et al.
Publicado: (2023)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Potential solutions for manufacture of CAR T cells in cancer immunotherapy
por: Blache, Ulrich, et al.
Publicado: (2022)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells
por: Wong, Sandy W., et al.
Publicado: (2021)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
por: Mishra, Abhinava K., et al.
Publicado: (2023)

人源化BCMA CAR-T细胞挽救治疗鼠源BCMA CAR-T细胞治疗后再进展的难治多发性骨髓瘤二例
Publicado: (2021)

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy
por: Georgi, Thomas Walter, et al.
Publicado: (2023)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
por: Berahovich, Robert, et al.
Publicado: (2018)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mgrjqd2f31gpshqo93a60so6ba